as1409
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00625768)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- FibronectinBINDING AGENT
FN1 binding agent
- Interleukin-12 subunit betaINHIBITOR
IL12B inhibitor
- FibronectinINHIBITOR
FN1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109413 ↗
Also known as
- as1409
- as1409
- as1409
- as-1409
- hubc1-huil12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00625768 | Phase 1 | Jan 1, 2008 | Antisoma Research, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antisoma Research | For profit | 1 | 1 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1